Compare MGNX & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGNX | CHMI |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.8M | 93.0M |
| IPO Year | 2013 | N/A |
| Metric | MGNX | CHMI |
|---|---|---|
| Price | $3.59 | $2.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $4.60 | $3.00 |
| AVG Volume (30 Days) | ★ 852.2K | 233.4K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.14 | $61.13 |
| P/E Ratio | ★ N/A | $139.30 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.12 | $2.17 |
| 52 Week High | $3.88 | $3.14 |
| Indicator | MGNX | CHMI |
|---|---|---|
| Relative Strength Index (RSI) | 66.91 | 52.96 |
| Support Level | $1.48 | $2.49 |
| Resistance Level | N/A | $2.74 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 70.00 | 69.74 |
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.